ArticleLancet regional health. Americas2025
A national cross-sectional analysis of surveillance drug resistance mutations among recently diagnosed antiretroviral naïve Brazilian people with HIV.
Article in Lancet regional health. Americas, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Advancements in development of novel class of HIV protease inhibitors.Annals of medicine · 2026Review
- The "Porto Alegre HIV Charter": Confronting the HIV epidemic in Rio Grande do Sul, Southern Brazil.The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases · 2026Article
- Next-Generation HIV-1 Therapeutics in Co-Endemic Settings.Biomedicines · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Brazil pioneered free and universal HIV antiretroviral therapy (ART) access in 1996. This study evaluated the prevalence of surveillance drug resistance mutations (SDRM) among individuals newly diagnosed with HIV and initiating ART. Methods: Using WHO HIV Threshold Survey methodology, participants were recruited from seven major cities, representing all Brazilian macro-regions. Dried blood spots collected between August 2021 and November 2023 were transported at room temperature to a central laboratory for genotyping. Findings: A total of 327 samples were analyzed, 271 (82.9%) were males. The self-reported ethnic distribution was obtained from 257 people, including 92 white (35.8%), 115 brown (44,7%), 46 black (17.9%), 2 indigenous (0.8%), and 2 Asian (0.8%) people. Mean/median CD4+ T-cell counts were 377/325 cells/μL, and mean/median viral load was 468,000/71,800 copies/mL. Overall SDRM prevalence was 11.6%, with regional values of 16.0% (Rio de Janeiro), 11.5% (Santos), 13.0% (Belém), 11.6% (Porto Alegre), 10.6% (Itajaí), 10.6% (Brasília), and 9.0% (Salvador). Resistance prevalence by class was 3.4% for nucleoside reverse transcriptase inhibitors, 5.2% for non-nucleoside reverse transcriptase inhibitors, 1.5% for protease inhibitors, and 1.8% for integrase strand transfer inhibitors (INSTI). One individual harbored the dolutegravir-associated R263K mutation. Compared to a prior survey conducted a decade earlier, subtype C prevalence increased markedly, and a probable new circulating recombinant form was detected. Interpretation: Nationwide SDRM prevalence in Brazil remains stable relative to data from 10 years ago. However, the emergence of low-level INSTI SDRM, including dolutegravir-specific resistance, is noteworthy. These results emphasize the importance of continuous SDRM and HIV genetic diversity surveillance. Sustained molecular monitoring is essential for optimizing prevention strategies and preserving long-term treatment effectiveness. Funding: FAPESP and CNPq.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.